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Toll-like receptor 9 (TLR9) triggering is a promising novel strategy to combat cancer as it induces innate and adaptive immunity
responses. B-cell lymphoma is unique in this context as tumor cells express TLR9 and may harbor latent Epstein-Barr virus
(EBV), a gamma-herpesvirus with remarkable oncogenic potential when latent. Latent EBV may be promoted by TLR9 triggering
via suppression of lytic EBV. Here, we elaborated an initial assessment of the impact of TLR9 triggering on EBV-positive and
EBV-negative B-cell lymphoma using Burkitt’s lymphoma (BL) cell lines as an in vitro model. We show that, independent of the
presenceofEBV,theTLR9ligandoligodeoxynucleotide(ODN)CpG-2006mayormaynotinducecaspase-dependentcelldeathin
BL cells. Moreover, ODN CpG-2006-induced cell death responses of BL cells were associated with TLR9 single-nucleotide
polymorphisms (SNPs) rs5743836 or rs352140, which we detected in primary BL tumors and in peripheral blood from healthy
individuals at similar frequencies. Thus, our ﬁndings suggest that the effect of TLR9 agonists on BL cells should be tested
in vitro before installment of therapy and TLR9 SNPs in BL patients should be determined as potential biological markers for the
therapeutic response to treatment targeting innate immunity.
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Toll-like receptors (TLRs) are important players of the innate
immune system,
1 and expression of the 10 TLRs known in
humans
2,3 depends on the cell subset and differentiation
status.
4–6 TLR9 is preferentially expressed by B cells and
plasmacytoid dendritic cells (reviewed in reference Iwasaki
and Medzhitov
1). Synthetic TLR9 ligands, short oligode-
oxynucleotides (ODN) with unmethylated CpG motifs,
7 acti-
vate TLR9 that recruits the adapter protein myeloid differentia-
tion factor 88 (MyD88) and induces a cascade leading to the
nuclear translocation of the transcription factor nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB).
2
The immune response following TLR9 engagement is
highly desirable for cancer treatment.
8 Synthetic TLR9
agonistsareregardedaspotentialanti-canceragents.Clinical
trials have shown promising results for the treatment of
various cancer types with CpG ODNs.
9 Their effects can
be indirect by enhancing the anti-tumor immune response
or direct by inducing apoptosis in the malignant cells. Direct
effects would be expected for B-cell malignancies as they
express TLR9. B-cell activation can eventually lead to
activation-induced cell death of cancer cells and therefore
support anti-cancer treatment.
10 Nevertheless, the TLR9
agonist effects vary strongly between B-cell cancer types,
and the responses of B-cell lymphomas to ODN CpG-2006
show high variability.
11 Thus, the effects of CpG ODNs
on B-cell malignancies are not predictable. Moreover,
CpG ODN treatment has tumor-promoting effects on benign
B cells and strongly enhances their proliferation and
differentiation.
12-14
Stimulation of TLR9 with ODN CpG-2006 suppresses
lytic reactivation of Epstein-Barr virus (EBV), a B-cell
tropic gamma-herpesvirus, and can thereby promote latent
EBV.
15,16 The latter is associated with several types of B-cell
lymphomas including Burkitt’s lymphoma (BL).
17 EBV is
present in nearly all cases of the high-incidence form of BL
(‘endemic BL’), in up to 85% of the intermediate-incidence
cases, and in 15% of the low-incidence cases (‘sporadic’ BL).
Up to 40% of BL in human immunodeﬁciency virus carriers
harbor EBV.
17 As latent EBV exhibits unique growth
transformation potential on B cells in vitro
18 and TLR9
triggering enhances EBV-induced B-cell transformation
19
and promotes latent EBV in vitro,
15,16 TLR9 stimulation in
the treatment of EBV-positive BL could provoke detrimental
rather than beneﬁcial outcomes.
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www.nature.com/cddisSingle-nucleotide polymorphisms (SNPs) of TLR9 are
associated with increased risk for certain B-cell lymphomas
20
and have the potential to exhibit deregulation of signaling
thereby promoting tumorigenesis. The responses of TLR9
SNPs in B-cell tumors to CpG ODN treatment are not
reported.
Here, we used BL-cell lines to model direct effects of TLR9
stimulation on malignant cells, investigate the inﬂuence of
EBV,andassesstheimpactofTLR9SNPs,whichwefoundin
primary BL samples or in healthy primary cells.
Results
TLR9 triggering alters gene expression and activates
Akata cells in a MyD88-dependent manner. CpG ODNs
activate B cells by impacting on gene expression.
21 We
asked how the gene expression pattern of BL cells is affected
by TLR9 triggering using CpG ODN. We performed a
microarray analysis comparing ODN CpG-2006-treated
versus untreated Akata cells. Most of the Z2-fold changes
in gene expression were upregulation and only few down-
regulation. Among upregulated genes, we were mainly
interested in those involved in cytokine (human interleukin
10; hIL-10) and chemokine expression (CXCL10), B-cell
activation (CD40), transcription (NF-kB) and apoptosis (FAS)
as these genes are those that preferentially determine
cell proliferation and survival (Supplementary Table 1).
Thirteen genes, including two regulating cell cycle, one
transcription factor, one involved in B-cell differentiation and
apoptosis, four of diverse functions and four of unknown
function, showed downregulation following ODN CpG-2006
treatment (Supplementary Table 2).
WeearlierconﬁrmedthatTLR9triggeringofAkatacellswith
ODN CpG-2006 increases hIL-10 expression and leads
to the translocation of NF-kB to the nucleus.
16 To validate a
marker for B-cell activation, in this context, we measured
CD40 expression by ﬂow cytometry. CD40 expression was
increased upon ODN CpG-2006 treatment (Figure 1a). After
48h, CD40 expression on ODN CpG-2006-treated cells was
increased 2.7-fold compared with untreated cells (Figures 1a
and b). Surprisingly, the control ODN GpC-2006, which is
similartoODNCpG-2006butlackstheCpGmotifs,alsoledto
a 2.4-fold increase in CD40 expression (Figures 1a and b).
This might reﬂect a TLR9-independent mechanism or the
ability of the control ODN to stimulate TLR9 in BL cells.
To clarify this point, we used Akata cells overexpressing a
dominant-negative mutant of the adaptor protein MyD88
(DN-MyD88).
16 Treatment with ODN CpG-2006 or ODN
GpC-2006 induced increased CD40 expression, corroborat-
ing our ﬁrst observation (Figure 1c). By contrast, neither ODN
Figure 1 TLR9agonists induceCD40expressioninAkatacellsinaMyD88-dependent manner. Akatacellsor DN-MyD88Akatacellswereleft untreatedor treatedwith 0.5mM
ODN CpG-2006 or ODN GpC-2006 for 48h. After 6, 24 and 48h, 10
5 cells were harvested, washed with PBS and stained with PE-Cy5-conjugated mouse anti-human CD40
antibody or a PE-Cy5 mouse IgG1k isotype control and analyzed with a ﬂow cytometer. (a) FACS plots of Akata cells. Isotype control: shaded gray line; anti-CD40
PE-Cy5: black line. Numbers indicate the mean ﬂuorescence intensity (MFI) (b) Quantiﬁcation of (a). (c) Comparison of CD40 expression in Akata cells andDN-MyD88 Akata cells
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Cell Death and DiseaseCpG-2006 nor ODN GpC-2006 signiﬁcantly induced an
increase in CD40 expression in DN-MyD88 Akata cells
(Figure 1c). Finally, we validated the ODN CpG-2006
treatment-induced upregulation of STAT3 (Supplementary
Table 1) by quantitative real-time polymerase chain reaction
(qRT-PCR) and conﬁrmed activation of STAT3 by western
blot (data not shown).
Collectively, we validated our microarray data showing
that triggering with ODN CpG-2006 activates Akata cells to
induce CD40 and STAT3 expression. Moreover, our results
indicated that both ODNs used here act in a MyD88-
dependent manner and that the ODN lacking CpG motifs
activatesAkata cellsto a similar extent as the ODN containing
CpG motifs.
TLR9 triggering by CpG ODN does not impact on the cell
cycle of Akata cells. TLR9 triggering leads to cell cycle
entry and proliferation of B chronic lymphatic leukemia
cells.
11,12,22 We analyzed the cell cycle of mock-treated or
ODN CpG-2006-treated Akata cells after initiation of treat-
ment by propidium iodide staining and ﬂow cytometry. Most
cells were in the S phase during the time frame of 48h
(Supplementary Figure 1). Treatment with ODN CpG-2006
did not alter the cell cycle compared with mock treatment.
Similar results were obtained with Akata31 cells (data not
shown), an EBV-negative subclone of Akata cells.
23 Thus,
although TLR9 triggering by ODN CpG-2006 resulted in BL-
cell activation based on increased expression of certain
genes, it did not seem to inﬂuence the cell cycle.
ODN-induced cell death of BL Akata cells is MyD88-
dependent. Treatment with ODN GpC-2006 unexpectedly
induced CD40 upregulation in Akata cells in a MyD88-
dependent manner similar to treatment with ODN CpG-2006.
We determined whether treatment with distinct TLR9 ligands
would similarly result in a MyD88-dependent effect on cell
survival. Also, we explored whether a class A ODN, that
displays low speciﬁcity for B cells, exerts similar effects on
BL cells as class B ODNs that possess a high speciﬁcity for
B cells. Therefore, we treated Akata cells or DN-MyD88
Akata cells with ODN CpG-2216 (type A), ODN CpG-2006
(type B) and ODN GpC-2006 (type B control), respectively,
and analyzed the viability of the cells by Trypan Blue
exclusion assay and PE-Annexin V/7-amino-actinomycin
(7-AAD) staining. The Trypan Blue exclusion assay showed
that treatment of Akata cells with ODN CpG-2006 or ODN
GpC-2006 reduced the survival of cells within 48h to below
50% of not treated cells and treatment with ODN CpG-2216
to almost 50% of not treated cells after 72h (Figure 2a). By
contrast, the survival of DN-MyD88 Akata cells was not, if at
all, reduced by treatment with any of the three ODNs for 72h
(Figure 2a). These ﬁndings were corroborated by the
Annexin V/7-AAD assay revealing that the viability of Akata
cells was drastically affected by treatment with class B ODNs
and to a lesser extent with class A ODN, contrasting
DN-MyD88 Akata cells that were not affected by treatment
with ODNs for 72h (Figure 2b and quantiﬁcation in
Figure 2c). Thus, treatment of Akata cells with ODNs CpG-
2006 and GpC-2006 triggers TLR9 signaling via MyD88 and
results in cell death.
ODN-induced cell death of BL Akata cells is caspase-
dependent. To explore the mechanism of ODN-induced cell
death of Akata cells we set out to investigate whether
caspases were involved. Thus, the activity of caspase-3
and -7 in ODN-treated Akata cells was detected using a
luminogenic substrate, which gives rise to a luminescent
signal proportional to caspase-3/7 activity. Triggering with
TLR9 ligands for 48h increased the luminescent signal about
twofold as compared with no triggering. This increase was
abolished by treatment with the caspase inhibitor z-VAD-
FMK (Figure 3a), indicating that TLR9 triggering resulted in
increased caspase activity in Akata cells and that this activity
was not increased if cells were concomitantly treated with a
caspase inhibitor. These ﬁndings were corroborated using
PI staining, which indicate that Akata cell death induced by
treatment with ODNs can be abrogated by the caspase
inhibitor z-VAD-FMK (Figure 3b); and by western blotting
showing that PARP cleavage is increased by ODN treatment
and can be reduced by the inhibitor (Figure 3c). Thus,
ODN-induced cell death of Akata cells was found to be
caspase-3/7 dependent and therefore due to apoptosis.
Survival of distinct BL cells following treatment with
CpG ODNs differs considerably, independently of the
presence of EBV. ODN CpG-2006 suppresses EBV lytic
gene expression in Akata cells and primary B cells promoting
latent EBV that may provide cell survival signals.
15,16 As we
observed Akata cell death upon TLR9 triggering, we asked
whether the absence of EBV would result in even more
pronounced cell death following TLR9 triggering. Hence, we
tested whether TLR9 agonists affect the survival of EBV-
positive Akata cells and of EBV-negative Akata31 cells in a
similar fashion. Treatment with ODN CpG-2006 or ODN
GpC-2006 strongly decreased the percentages of surviving
Akata cells or Akata 31 cells between 24 and 72h compared
with untreated cells. Nevertheless, the effect on Akata 31
cells was less marked (Figure 4a). The percentages of
apoptotic Akata 31 cells assessed by Annexin V/7-AAD
staining after 72h of treatment, however, were comparable to
those of Akata cells (Figure 4b). Treatment with ODN CpG-
2216, ODN CpG-2006 or ODN GpC-2006 resulted in similar
respective decreases in viability of Akata cells versus
Akata31 cells due to apoptosis. Treatment with class A
ODN CpG-2216 exhibited almost no negative impact on cell
survival compared with treatment with the class B ODNs
CpG-2006 and GpC-2006 (Figure 4b). These results showed
that EBV-negative Akata31 cells exhibited a higher level
of spontaneous cell death by apoptosis compared with
EBV-positive Akata cells and corroborated the lower effect
of TLR9 triggering by class A ODN compared with triggering
by class B ODNs. Moreover, the results suggested that
the presence of EBV does not prevent EBV-positive Akata
cells from TLR9 triggering-induced cell death compared with
EBV-negative Akata31 cells.
Next, we investigated whether our observations in
EBV-positive versus EBV-negative BL cells hold true in BL
cells other than Akata. To this end, we used EBV-positive BL
cells Mutu-I and EBV-negative BL cells BJAB and Ramos.
Treatment with ODN CpG-2006 or with ODN GpC-2006 did
not affect Mutu-I cell or BJAB cell survival (Figure 4c) but it
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Cell Death and Diseasedecreased Ramos cell survival between 48 and 72h
(Figure 4c). Thus, the survival of BL cells following TLR9
triggering considerably differs between distinct BL cells and
doesnot seemto dependonthe presence or absenceof EBV.
Exogenous hIL-10 does not prevent ODN CpG-2006-
induced cell death. hIL-10 has an important role in B-cell
lymphoma biology as it seems to act as autocrine growth
factor.
22,24–26 We previously reported
16 and corroborate
here, a strong hIL-10 induction in Akata cells following TLR9
triggering with ODN CpG-2006 (Supplementary Table 1).
Nevertheless, the very same treatment resulted in drastic
Akata cell death (Figure 2), suggesting that the latter could
not be prevented by the induction of hIL-10 expression.
Figure 2 ThecelldeathinducedbyTLR9agonistsis MyD88dependent.Akata cellsandDN-MyD88Akatacellswereincubatedwith mediumonly,ODNCpG-2216, ODN
CpG-2006 or ODN GpC-2006. (a) The cell survival was assessed by Trypan Blue exclusion assay 0, 24, 48 and 72h after treatment. (b) Apoptosis assay after 72h of
treatment. 10
5 cells were stained with PE-Annexin V/7-AAD and analyzed by ﬂow cytometry. The double-negative population represents viable cells whereas PE-Annexin
V-positive or double-positive populations represent non-viable cells. (c) Quantiﬁcation of the Annexin V/7-AAD assay in (b). Shown are the results of a representative
experiment of two experiments (showing mean values)
Burkitt’s lymphoma and TLR9 polymorphisms
J Noack et al
4
Cell Death and DiseaseOtherwise, a recent report suggested that treatment with
ODN CpG-2006-induced hIL-10 in chronic lymphocytic
leukemia B cells mediating their cell death.
10 Therefore, we
treated Akata cells and DN-MyD88 Akata cells with ODN
CpG-2006, recombinant hIL-10 (rhIL-10) or a combination
thereof. The concentration of rhIL-10 was based on the peak
hIL-10 protein concentration induced by ODN CpG-2006
treatment in Akata cells.
16 Additionally, ODN CpG-2006
treatment was reiterated at 48h in a fraction of BL cells.
As expected, treatment with ODN CpG-2006 for 72h
reduced the viability of Akata cells to o20% but did not
reduce viability of DN-MyD88 Akata cells compared with no
treatment (Figures 5a–c). Reiterated treatment with ODN
CpG-2006 after 48h did not further reduce viability of Akata
cells compared with one-time treatment and did not reduce
viability of DN-MyD88 Akata cells (Figure 5a–c). Treatment
with rhIL-10 for 72h also did not reduce viability of Akata cells
or DN-MyD88 Akata cells compared with no treatment.
Treatment with rhIL-10 did not counteract ODN CpG-2006
treatment-induced reduction of BL cell viability or further
decreased their viability. DN-MyD88 Akata cells were not
affected by any of the treatments (Figures 5a–c). Thus,
maximal negative impact of ODN CpG-2006 on cell survival in
Akata cells occurred after one treatment. Moreover, rhIL-10
did not change the number of viable Akata cells, or rescue
Akata cells from ODN CpG-2006 treatment-induced cell
death. This suggested that hIL-10 cannot counteract TLR9
triggering-induced cell activation resulting in death of Akata
cells and is not responsible for their cell death.
BL cells express distinct hIL-10 mRNA and hIL-10 levels
following TLR9 triggering. The distinct survival of BL cells
following TLR9 triggering with ODN CpG could be because of
distinct magnitudes of ensuing cellular responses. The
induction of hIL-10 following ODN CpG treatment can be
regarded as a surrogate marker for the magnitude of cell
activation mediated by TLR9 triggering. Thus, we assessed
hIL-10 mRNA expression in BL cells treated with ODN
CpG-2006 or ODN GpC-2006. All ﬁve BL cell lines tested
expressed hIL-10 mRNA following treatment with ODN CpG-
2006, the values peaking preferentially at 6h post treatment
(Figure 6a). Peak hIL-10 mRNA expression levels varied
from 1.3 transcripts over HMBS in Ramos BL cells to
48 transcripts in Mutu-I BL cells. Treatment with ODN
GpC-2006 also resulted in induction of hIL-10 mRNA
expression but in lower levels, except in Akata cells. Similar
variation of results was observed when analyzing hIL-10
protein levels (Figure 6b). Thus, TLR9 triggering of distinct
BL cells resulted in a broad range of hIL-10 mRNA and
hIL-10 protein expression levels, and the magnitude of the
level seemed independent of EBV status.
Next, we determined TLR9 mRNA expression levels in BL
cells by qRT-PCR. Although distinct BL cells showed up to
sixfold different relative TLR9 mRNA expression levels
Figure3 TLR9ligandsinducecelldeathofAkatacellsviacaspaseactivation.(a)Caspaseactivityin0.5 10
6Akatacellsmeasured48haftertreatment withtheTLR9ligands
ODN CpG-2006, ODN GpC-2006 and ODN CpG-2216 without or with z-VAD-FMK. Cells were incubated with the Caspase-Glo luminogenic substrate to detect activated caspases
and analyzed with a luminometer. Results represent the relative light units generated by active caspases 3 and 7. Shown in the bar graph are the results of a representative
experiment out of three performed in duplicate. (b) Treatment of Akata cells with caspase inhibitor z-VAD-FMK reduces TLR9 ligand-induced cell death.
10
6 Akata cells were treated with the TLR9 ligands ODN CpG-2006, ODN GpC-2006 or ODN CpG-2216 with or without addition of z-VAD-FMK. After 48h, cells were stained
with PI and analyzed by ﬂow cytometry. Shown are the results of a representative experiment out of twoexperiments performed induplicate. (c) Treatmentof Akata cells with TLR9
ligand induces PARP cleavage. Lysates from 10
6 Akata cells 48h after incubation with the TLR9 ligands ODN CpG-2216, ODN CpG-2006 and ODN GpC-2006 with or without
z-VAD-FMK were analyzed by immunoblotting for PARP cleavage. The relative density of the cleaved PARP was calculated using densitometry and normalized to b-actin
Burkitt’s lymphoma and TLR9 polymorphisms
J Noack et al
5
Cell Death and Disease(Figure 6c), ODN CpG-2006 treatment-induced hIL-10 mRNA
peakexpressionlevelsdid notcorrelatewiththerelative TLR9
mRNA expression levels (Figure 6d). Collectively, TLR9
triggering in distinct BL cells resulted in distinct hIL-10 mRNA
expression,notlinkedtopresenceorabsenceofEBV,andnot
correlated to TLR9 mRNA expression levels.
TLR9 polymorphisms of BL cells might correlate with
distinct responses to TLR9 triggering. TLR9 polymorph-
isms in patients are linked to different outcomes of
inﬂammatory diseases and the development of cancer.
27,28
We hypothesized that TLR9 polymorphisms could be a
possible explanation for our observations. Thus, we isolated
the genomic DNA from BL cell lines and analyzed it for the
presence of TLR9 polymorphisms. We found speciﬁc SNPs
for each cell line, allowing segregation of the BL cell lines into
three groups (Table 1):  1237 TT/1635 GA (Akata
and Akata 31),  1237 TT/1635 GG (Ramos) and  1237
TC/1635 GG (Mutu-I and BJAB). This sub-grouping corre-
lated with the degree of BL-cell survival in response to ODN
Figure 4 TLR9 agonists induce cell death of Akata cells and Akata31 BL cells, but not of Mutu-I BL cells or BJAB BL cells, while Ramos BL cells are intermediately
affected.10
6 cells weretreatedwith theTLR9ligands ODNCpG-2216, ODNCpG-2006and ODNGpC-2006. (a) Survivalof untreated,ODNCpG-2006-treated or ODNGpC-
2006-treated Akata cellsand Akata31 BLcells was assessedby Trypan Blueexclusion assayandcountingof viable anddead cellsand comparedwith theuntreatedcontrol.
(b)ApoptosisofAkataandAkata31BLcellsafter72hoftreatment.10
5cellswerestainedwithPE-AnnexinV/7-AADandanalyzedbyﬂowcytometry(leftpanel);percentages
ofPE-AnnexinV/7-AADnegativecells(rightpanel).(c)Thesurvivalofuntreated,ODNCpG-2006orODNGpC-2006-treatedMutu-I,BJABandRamosBLcellswasevaluated
by Trypan Blue exclusion. Shown are the results of a representative experiment out of at least two experiments performed in duplicate (showing mean values) or in triplicate
(showing mean values±S.E.M., indicated by error bars)
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Cell Death and Diseasetreatment (Figure 4c), suggesting that the distinct BL-cell
responses to TLR 9 triggering may depend on the SNPs
present.
Next, we analyzed TLR9 SNPs in genomic DNA from
primary BLs or blood from healthy individuals. Indeed,
we found the TLR9 SNPs detected in our BL cell lines in
primary BL samples and blood of healthy individuals
(Table 2). Importantly, the TLR9 SNP frequencies were
statistically not signiﬁcantly different between BL cell lines,
primary BLs and blood from healthy individuals, respectively.
This suggested that if the direct response to TLR9
agonists depends on the TLR9 SNP, this could be an
important factor regarding the treatment of BL patients by
TLR9 triggering.
Figure5 hIL-10doesnotinﬂuenceODNCpG-2006-inducedcelldeath.AkatacellsandDN-MyD88Akatacellswereincubatedwithmediumonly,0.5mMODNCpG-2006,
900pg/ml rhIL-10 or combinationof ODN CpG-2006 and rhIL-10. To one ODN CpG-2006-stimulated sample, 0.5mM ODN CpG-2006 was added again after 48h (rep. CpG-
2006). (a) The cell viability was monitored by the Trypan Blue exclusion test 0, 48 and 72h after treatment. (b) After 72h cells were harvested and 10
5 cells were stained with
PE-Annexin V/7-AAD and analyzed by ﬂow cytometry. (c) Quantiﬁcation of (b)
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Cell Death and DiseaseDiscussion
We analyzed the effects of TLR9 agonists on BL cell lines
as an in vitro model for B-cell tumor. We found that treatment
with TLR9 ligands induces distinct cytokine expression and
cell death responses in distinct BL cells. Cell death was
(i) dependent on TLR9-MyD88 signaling, (ii) occurred conco-
mitantly with activation and could be suppressed by pan
caspase inhibitors, (iii) was not dependent on the presence or
absenceofEBVinthetumorcellsand(iv)wasassociatedwith
SNPs in the TLR9 gene. Our results suggest that individua-
lized in vitro pretesting of BL responses to CpG ODNs could
helptopredicttheoutcomeoftherapeuticTLR9 triggeringand
tailor adjuvant molecular treatment of BL.
OurobservationthatBLcellsofdifferentoriginshowdistinct
cell survival following TLR9 triggering is novel. We previously
demonstrated that TLR9 triggering counteracts lytic
EBV reactivation in BL cells and promotes latent EBV that
is associated with B-cell lymphoproliferation.
16 Here, we
observed CpG type B ODN-induced cell death by apoptosis
in EBV-positive Akata and EBV-negative Akata31 cells, but
not or to a much lower extent in the other EBV-positive or
EBV-negative BL cell lines tested. Thus, the EBV status
of the tumor cells does not rule the responses of BL cells to
TLR9 triggering.
TLR9-triggered BL cells consistently upregulated hIL-10
expression. hIL-10 inﬂuences the development and growth of
B cells
29 and acts as an autocrine growth factor for different
B-cell lymphomas.
25,26,30 Importantly, here, rhIL-10 did
Figure 6 Treatment of BL cell lines with TLR9 agonists induces distinct hIL-10 mRNA and hIL-10 expression levels. (a) TLR9 triggering results in a wide range of hIL-10
mRNA expression levels. BL cells were left untreated or treated with 0.5mM ODN CpG-2006 or ODN GpC-2006 for the indicated time points. (b) hIL-10 protein expression
levelsintheculturesupernatantsofBLcelllines6haftertreatmentornotreatmentasin(a)measuredbyELISA.(c)TLR9mRNAexpressionlevelsdifferbetweenBLcelllines
by up to sixfold. EBV-positive (black bars) and EBV-negative (gray bars) BL cells. (d) The hIL-10 mRNA peak expression responses to ODN CpG-2006 did not correlate with
the corresponding relative TLR9 mRNA levels. Total RNA of 10
6 cells was isolated and transcribed into cDNA. HMBS, hIL-10 or TLR9 mRNA expression levels were
determined by qRT-PCR. The Ct values for hIL-10 and TLR9 were normalized to the Ct values of the housekeeping gene HMBS. Maximal values of relative hIL-10 mRNA
expression werecorrelatedwith therespectiverelativeTLR9mRNAexpressionusingatwo-tailedPearson’scorrelation.Shownare theresultsofarepresentative experiment
out of at least two experiments performed in duplicate (showing mean values)
Table 1 TLR9 single-nucleotide polymorphisms in the ﬁve investigated BL-cell
lines
Single-nucleotide
polymorphism
BL cell Epstein-Barr rs5743836 rs352140
line virus  1237 T/C 2848 G/A (P545P)
Akata Positive T/T G/A
Akata 31 Negative T/T G/A
Ramos Negative T/T G/G
Mutu-I Positive T/C G/G
BJAB Negative T/C G/G
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Cell Death and Diseaseneither prevent nor enhance cell death induced by TLR9
triggering. hIL-10, as an anti-inﬂammatory cytokine, inhibits
the Th1 immune response
31 and this effect would be
detrimental in cancer therapy that is based on intact or
enhancedimmune responses,
9as anunintended proliferation
of the malignant cells could be provoked. Thus, the function of
CpG type B ODN-induced hIL-10 expression in BL cells
seems to considerably differ from that in chronic lymphocytic
leukemia B cells that were reported to undergo hIL-10-
mediated apoptosis.
10
Surprisingly, ODN GpC-2006 induced cell death to the
same extent as ODN CpG-2006. ODN GpC-2006 binds to
TLR9, but in contrast to CpG-2006 it does not lead to TLR9
signaling in HEK293 cells or to changes in the secondary
structure of the ectodomain.
32 Therefore, we examined
whether downstream signaling of TLR9 via MyD88 is involved
inthe inductionofcelldeath.Indeed,experimentsusingAkata
cells overexpressing a MyD88 dominant-negative mutant
indicated that both ODNs induce cell death of BL cells in a
MyD88-dependent manner. Others demonstrated that ODNs
inducecelldeathindependentlyoftheCpGmotif,ofTLR9
33or
even of the whole-ODN sequence.
34 Another pathway
that is triggered by CpG ODNs, but is TLR9-independent,
was described in monocytes and involves the activation of the
Src family kinases Lyn and Hck.
35 In our experiments, BL cell
death induced by TLR9 triggering correlated with increased
caspase activity and was caspase-dependent, thus most
likely due to apoptosis.
The BL cell lines tested differed in their TLR9 mRNA
expression level and TLR9 SNPs. mRNA expression did not
correlate with cell death responses to TLR9 triggering, but the
distinct TLR9 SNPs did. The role of TLR9 SNPs in BL is
unknown. To start to investigate this we analyzed the
frequencies of given SNPs in BL patients and healthy
individuals and found them to be similar. A recent report
suggests that the rs5743836 polymorphism, which was also
detected here, confers an increased risk for non-Hodgkin
lymphoma in people from Portugal and Italy but not from the
United States.
20 The association of the C allele rs5743836
with lack of cell death upon TLR9 triggering observed here in
the Mutu-I and BJAB BL cell lines is striking. It does not allow
establishing a causal link, but justiﬁes the hypothesis that the
distinct cell death responses upon CpG ODN treatment in
BL cells may be linked to TLR9 SNPs. Notably, the C allele of
rs5743836 exhibits greater NF-kB-binding afﬁnity because of
an additional NF-kB transcriptional binding site that may lead
to increased production of proinﬂammatory cytokines.
36
Hence, the presence of the C allele seems to result in
enhanced NF-kB activation following TLR9 triggering.
This may lead to protection of ODN CpG treatment-
induced apoptosis that can be observed in BL cells without
the C allele.
In conclusion, therapeutic TLR9 triggering appears to be a
double-edge sword that may induce apoptosis, or enhance
lymphoproliferation. Our ﬁndings suggest that the effect of
TLR9 agonists on BL cells should be tested in vitro before
installment of therapy and that TLR9 SNPs in BL patients
should be evaluated as potential biological markers for the
response to treatment targeting innate immunity.
Materials and Methods
Cell lines. The EBV-positive BL cell lines Akata and Mutu-I, and the
EBV-negative BL cell lines Akata 31, BJAB and Ramos were grown in RPMI
1640 supplemented with 10% heat-inactivated fetal calf serum, streptomycin
(100mg/ml), penicillin (100U/ml) and L-glutamine (2mM). EBV-positive BL Akata
cells expressing a dominant-negative MyD88 (DN-MyD88 Akata)
16 were grown in
the same medium supplemented with 0.4mg/ml G418 (Promega, Mannheim,
Germany).
Primary BL tissue samples and peripheral blood from healthy
individuals. BLs were retrieved from the database of the Institute of Surgical
Pathology, University Hospital of Zurich (PathoPro Software, Institute of Medical
Software, Saarbru ¨cken, Germany). The BL diagnosis was performed according to
the WHO classiﬁcation of tumors of hematopoietic and lymphoid tissues.
37 DNA
was extracted from parafﬁn-embedded whole-tissue sections, according to
standard procedures. This study was in accordance with Swiss laws and
approved by the ofﬁcial authorities of the ethical committee of the Canton of Zurich
(StV2-2007). Peripheral blood was collected from 402 healthy blood donors
(aged 19–70 years) who were randomly selected according to the criteria of the
Swiss Red Cross.
38
Single-nucleotide polymorphism analysis. Whole-genomic DNA was
extracted with the DNeasy Blood and Tissue Kit (Qiagen, Hombrechtikon,
Switzerland) according to the manufacturer’s instructions. Genotyping of the TLR9
polymorphisms –1237 T/C (rs5743836) and 2848 G/A (rs352140) was done by
tetra-primer assays as previously described.
39
Treatment with TLR9 agonists. Cells were split to a density of 0.5 10
6
cells/ml. The TLR9 ligands ODN CpG-2216 (type A), ODN CpG-2006 (type B) and
ODN GpC-2006 (type B control) were applied at concentrations of 0.5mM. ODN
(LabForce-InvivoGen, Nunningen, Switzerland) sequences: ODN CpG-2216:
50-ggGGGACGATCGTCgggggg-30, bases are phosphodiester (capital letters)
or phosphorothioate (lower case); ODN CpG-2006: 50-tcgtcgttttgtcgttttgtcgtt-30,
full phosphorothioate backbone; ODN GpC-2006: 50-tgctgcttttgtgcttttgtgctt-30,
full phosphorothioate backbone.
Microarray analysis. Akata cells were mock treated or treated with CpG-
2006, and harvested 6h later. Total RNA was isolated with RNeasy mini kit
(Qiagen) according to the manufacturer’s instructions. Microarray analysis was
performed at the Functional Genomic Center Zurich (University of Zurich, Zurich,
Switzerland). Human Exon 1.0 ST Array chips (Affymetrix, Santa Clara, CA, USA)
and Genespring GX software (Agilent Technologies, Basel, Switzerland) were
used for the analysis. An at least twofold change in gene expression (upregulation
or downregulation) in the treated versus the mock-treated sample was regarded as
signiﬁcant.
qRT-PCR (Taqman). Total RNA was extracted from 10
6 cells with the
RNeasy Kit (Qiagen) and DNA was removed with DNA-free (Ambion Europe,
Huntingdon, Cambridgeshire, UK). 1mg of the puriﬁed RNA was used to generate
cDNA with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Table 2 Frequencies of TLR9 single-nucleotide polymorphisms in ﬁve BL-cell
lines, 15 primary BL tumors and blood samples from 402 healthy individuals
Single-nucleotide polymorphism
rs5743836
 1237 T/C
rs352140
2848 G/A
(P545P)
BL cell
lines
N
BL
tumors
N (%)
Healthy
individuals
N (%)
T/T G/G 1 4 (27) 178 (44)
T/T G/A 2 5 (33) 165 (41)
T/T A/A — 2 (13) —
T/C G/G — — 1 (0)
T/C G/A 2 1 (7) 55 (14)
T/C A/A — 3 (20) 5 (1)
The frequencies of the polymorphisms were statistically not signiﬁcantly
different
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Taqman primers and probes on ABI 7200 (Applied Biosystems). Data were
analyzed with the software SDS2.2 (Applied Biosystems). Delta cycle threshold
(Ct) values for the respective genes were normalized to HMBS.
Staining for surface antigens. 10
5 cells were stained with FITC mouse
anti-human IgM (Clone G20-127), PE-Cy5 mouse anti-human IgG (Clone
G18-145), PE mouse anti-human IgD (Clone IA6-2) or the respective isotype
controls, FITC IgG1k isotype control (Clone MOPC-21), PE-Cy5 mouse IgG1k
isotype control (Clone MOPC-21), PE mouse IgG2ak isotype control (Clone G155-
178) or PE-Cy5 anti-human CD40 (Cat. 555590) (all from BD Biosciences,
Allschwil, Switzerland) for 30min at 41C in the dark. Cells were counted with a
ﬂow cytometer (FACSCanto II, BD Biosciences).
Annexin V/7-AAD staining. To assess apoptotic, necrotic or dead and
viable cells, 10
5 cells were harvested, washed with phosphate-buffered saline
(PBS) and resuspended in 100ml Annexin V binding buffer (140mM NaCl, 2.5mM
CaCl2, 10mM HEPES, pH 7.4) and incubated with 5ml Annexin V and 5ml 7-AAD
(BD Biosciences) for 15min at room temperature in the dark. After addition of
200ml Annexin V binding buffer, cells were analyzed with the FACSCanto II ﬂow
cytometer (BD Biosciences).
Propidium Iodide staining. To discern between dead and viable cells,
treated cells were stained with 50mg/ml PI (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland) for 15min at room temperature and then analyzed with the
FACSCanto II ﬂow cytometer (BD Biosciences).
Protein isolation, quantiﬁcation and Western blot. Total protein
lysates were obtained after lysing the cells in RIPA complete buffer (50mM
Tris-HCl pH 7.5, 150mM NaCl, 2mM EDTA, 1% NP40 complemented with 0.1%
SDS, 1  EDTA-free protease inhibitor cocktail (Roche, Rotkreuz, Switzerland)).
Cell extracts were passed 10 times through a 25-G syringe. Protein content was
determined using the Pierce BCA Protein Assay Kit (ThermoScientiﬁc,
Erembodegem, Belgium), according to the manufacturer’s instructions. To analyze
protein expression by western blot, protein (20mg/well) was loaded into a
NuPAGE 4–12% Bis-Tris Gel (life technologies, Zug, Switzerland) and subjected
to SDS-PAGE electrophoresis, transferred electrophoretically to a nitrocellulose
membrane (GE Healthcare, Glattbrugg, Switzerland), incubated with rabbit anti-
PARP antibody or rabbit anti-b-Actin antibody, and subsequently with anti-rabbit
IgG, HRP-linked antibody (all diluted 1:1000 and from, Cell Signaling Technology
(Allschwil, Switzerland). The signal was detected with the ECL Western Blotting
Detection Reagents (GE Healthcare) and imaged using the LAS-3000 (Fujiﬁlm,
Dielsdorf, Switzerland) and image reader LA-3000 (Fujiﬁlm).
hIL-10 ELISA. hIL-10 protein concentrations were determined in
supernatants from TLR9-stimulated cultures by standard capture ELISA (Ready-
SET-Go, eBioscience, Vienna, Austria) according to the manufacturer’s
instructions Plates were read at 450nm once the substrate had developed,
and cytokine concentration was determined by extrapolation from the standard
curve.
Caspase-3/7 activity. Activity of caspase-3/7 was assessed with the
Caspase-Glo 3/7 Assay according to the manufacturer’s protocol (Promega,
Wallisellen, Switzerland). Cells, dispensed at 0.5 10
6 cells/ml/well in a 24-well
plate were treated with TLR9 ligands and incubated at 371C for 48h. At the end of
the incubation period, 100ml of Caspase-Glo 3/7 reagent was added to 100ml cell
suspension in a white-walled 96-well plate and incubated at room temperature for
1h. Luminescence intensity was determined using a Synergy HT Multi-Detection
Microplate Reader (BioTek, Luzern, Switzerland).
Treatment of BL cells with rhIL-10. One day before the experiment, the
cells were split to a density of 0.5 10
6 cells/ml. The next day, 10
6 cells were
incubated with 900pg rhIL-10/ml (Immunotools, Friesoythe, Germany) for the
indicated time points. This concentration corresponds to the hIL-10 protein
concentration induced by ODN CpG-2006 in Akata cells.
16
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